GlassScriptPhysician profile
Mark Allen Erdman
NPI 1164534665
$3,212.05
in general payments reported to CMS, 2019-2025
31 companies · $649 in 2025
The $649 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $121 · 2021: $336 · 2022: $628 · 2023: $704 · 2024: $528 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,881.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $407.04 | 2020-2025 | Puraply, Novachor, Affinity |
| Horizon Therapeutics Plc | $389.98 | 2020-2023 | Krystexxa |
| Amgen INC. | $234.31 | 2024 | Krystexxa |
| Abbvie INC. | $229.86 | 2022-2023 | |
| Paratek Pharmaceuticals, INC. | $192.50 | 2021-2025 | Nuzyra |
| Convatec INC. | $189.55 | 2023-2025 | |
| Kerecis Limited | $180.61 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Pacira Pharmaceuticals Incorporated | $146.82 | 2022 | |
| Averitas Pharma INC. | $138.62 | 2023-2025 | Qutenza |
| Ani Pharmaceuticals, INC. | $136.53 | 2025 | Purified Cortrophin Gel |
| Vertex Pharmaceuticals Incorporated | $128.34 | 2024-2025 | |
| Melinta Therapeutics, LLC | $125.00 | 2019 | |
| Smith+Nephew, INC. | $117.04 | 2021-2022 | |
| In2bones USA, LLC | $110.13 | 2022 | |
| Allergan, INC. | $78.76 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $48.75 | 2023-2025 | Proclaim |
| Grt US Holding, INC. | $38.55 | 2022 | |
| Biocomposites INC | $33.56 | 2024 | |
| Nevro Corp. | $31.94 | 2022 | |
| Medtronic, INC. | $30.80 | 2025 | Intellis Adaptivestim |
| Bioventus LLC | $28.40 | 2022 | |
| Merck Sharp & Dohme LLC | $27.65 | 2019 | |
| Next Science LLC | $25.95 | 2023 | Blastx, Surgx, Xperience |
| Lifenet Health | $21.96 | 2025 | Theragenesis Wound Matrix |
| Boston Scientific Corporation | $21.29 | 2024 | |
| Anika Therapeutics, INC. | $21.12 | 2024 | Integrity, Toe Motion |
| Heron Therapeutics, INC. | $20.53 | 2021 | |
| Hartmann USA, INC. | $14.81 | 2025 | Zetuvit Plus 10x10 P10 |
| Bsn Medical INC | $14.49 | 2022 | |
| Kci USA, INC. | $14.14 | 2019 | |
| Dynasplint Systems INC. | $13.02 | 2023 | Dynasplint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Erdman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.